Page 132 - Haematologica Vol. 107 - September 2022

ARTICLE - Effects of BT200 on VWF/FVIII in humans
K.D. Kovacevic et al.
FVIII half-life. This prolongs the half-life of VWF/FVIII, which could allow regular prophylaxis in patients with non-severe hemophilia A, as well as allowing VWD pa- tients to increase their VWF/FVIII levels.
Disclosures
JCG and SZ are founders of, and BJ and BM are consultants for Guardian Therapeutics. The other authors have no rel- evant conflicts of interest to declare.
Contributions
KDK and AB performed the pharmacokinetic and part of the pharmacodynamic analyses. JG, GGe, GGa, CS, CF and UD (the principal investigator) were responsible for conducting the trial. BJ and JCG designed the trial, wrote the protocol and SZ developed the analytical methods. PJ-S and PQ were
References
1. Lollar P. The association of factor VIII with von Willebrand factor. Mayo Clin Proc. 1991;66(5):524-534.
2. Ruggeri ZM, Mendolicchio GL. Interaction of von Willebrand factor with platelets and the vessel wall. Hamostaseologie. 2015;35(3):211-224.
3. Kiouptsi K, Reinhardt C. Physiological roles of the von Willebrand factor-factor VIII interaction. Subcell Biochem. 2020;94:437-464.
4. Lavin M, O'Donnell JS. How I treat low von Willebrand factor levels. Blood. 2019;133(8):795-804.
5. Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood. 2013;122(23):3735-3740.
6. Tomeo F, Mariz S, Brunetta AL, Stoyanova-Beninska V, Penttila K, Magrelli A. Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective. Br J Clin Pharmacol. 2021;87(11):4183-4196.
7. Kovacevic KD, Jilma B, Zhu S, et al. von Willebrand factor predicts mortality in ACS patients treated with potent P2Y12 antagonists and is inhibited by aptamer BT200 ex vivo. Thromb Haemost. 2020;120(9):1282-1290.
8. Spiel AO, Mayr FB, Ladani N, et al. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand factor mediated ex vivo platelet function in acute myocardial infarction. Platelets. 2009;20(5):334-340.
9. Buchtele N, Schwameis M, Gilbert JC, Schorgenhofer C, Jilma B. Targeting von Willebrand factor in ischaemic stroke: focus on clinical evidence. Thromb Haemost. 2018;118(6):959-978.
10. Markus HS, McCollum C, Imray C, Goulder MA, Gilbert J, King A. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. Stroke. 2011;42(8):2149-2153.
11. Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME, Knobl P, Jilma B. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;106(3):539-547.
12. Lammle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost. 2005;3(8):1663-1675.
responsible for laboratory analyses and for quality checking methods. MB performed the pharmokinetic/pharmodynamic modeling and wrote the pharmokinetic/pharmodynamic re- port. All authors contributed to both writing and critically re- viewing the manuscript.
Acknowledgments
This trial was sponsored by Guardian Therapeutics. We would like to thank the following staff members for their outstanding logistic support and help: Christa Drucker, Karin Petroczi, Sabine Schranz, RN and Sarah Ely, RN, BA, PgDip who also edited the manuscript.
Data-sharing statement
Upon a justified request, the principal investigator will grant access to the primary clinical trial data.
13. Cataland SR, Peyvandi F, Mannucci PM, et al. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol. 2012;87(4):430-432.
14. Jilma-Stohlawetz P, Gorczyca ME, Jilma B, Siller-Matula J, Gilbert JC, Knobl P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;105(3):545-552.
15. Knoebl P, Cataland S, Peyvandi F, et al. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost. 2020;18(2):479-484.
16. Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2017;15(7):1448-1452.
17. Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335-346.
18. Jilma B, Paulinska P, Jilma-Stohlawetz P, Gilbert JC, Hutabarat R, Knobl P. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb Haemost. 2010;104(3):563-570.
19. Jilma-Stohlawetz P, Knobl P, Gilbert JC, Jilma B. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. Thromb Haemost. 2012;108(2):284-290.
20. Jilma-Stohlawetz P, Gorczyca ME, Jilma B, Siller-Matula J, Gilbert JC, Knobl P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;105(3):545-552.
21. Zhu S, Gilbert JC, Hatala P, et al. The development and characterization of a long acting anti-thrombotic von Willebrand factor (VWF) aptamer. J Thromb Haemost. 2020;18(5):1113-1123.
22. Kovacevic KD, Gilbert JC, Jilma B. Pharmacokinetics, pharmacodynamics and safety of aptamers. Adv Drug Deliv Rev. 2018;134:36-50.
23. Fazavana J, Brophy TM, Chion A, et al. Investigating the clearance of VWF A-domains using site-directed PEGylation and
Haematologica | 107 September 2022
2131